• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒2型合并感染的新威胁及应对当前大流行的策略。

New threatening of SARS-CoV-2 coinfection and strategies to fight the current pandemic.

作者信息

Goel Nikky, Ahmad Razi, Fatima Huma, Khare Sunil Kumar

机构信息

Enzyme and Microbial Biochemistry Laboratory, Department of Chemistry Indian Institute of Technology Delhi, Hauz Khas, New Delhi 110016, India.

出版信息

Med Drug Discov. 2021 Jun;10:100089. doi: 10.1016/j.medidd.2021.100089. Epub 2021 Mar 17.

DOI:10.1016/j.medidd.2021.100089
PMID:33748740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7963520/
Abstract

Coronavirus disease (COVID-19) is a global pandemic. The COVID-19 outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has overloaded healthcare systems that need medication to be rapidly established, at least to minimize the incidence of COVID-19. The coinfection with other microorganisms has drastically affected human health. Due to the utmost necessity to treat the patient infected with COVID-19 earliest, poor diagnosis and misuse of antibiotics may lead the world where no more drugs are available even to treat mild infections. Besides, sanitizers and disinfectants used to help minimize widespread coronavirus infection risk also contribute to an increased risk of antimicrobial resistance. To ease the situation, zinc supplements' potentiality has been explored and found to be an effective element to boost the immune system. Zinc also prevents the entry of the virus by increasing the ciliary beat frequency. Furthermore, the limitations of current antiviral agents such as a narrow range and low bioavailability can be resolved using nanomaterials, which are considered an important therapeutic alternative for the next generation. Thus, the development of new antiviral nanoagents will significantly help tackle many potential challenges and knowledge gaps. This review paper provides profound insight into how COVID-19 and antimicrobial resistance (AMR) are interrelated and the possible implications and current strategies to fight the ongoing pandemic.

摘要

冠状病毒病(COVID-19)是一场全球大流行疾病。由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发的COVID-19疫情使医疗系统不堪重负,这些系统需要迅速确定治疗药物,至少要尽量降低COVID-19的发病率。与其他微生物的合并感染已严重影响人类健康。由于迫切需要尽早治疗感染COVID-19的患者,诊断不当和抗生素的滥用可能会导致世界面临无药可用的局面,甚至无法治疗轻度感染。此外,用于帮助降低冠状病毒广泛传播风险的消毒剂也会增加抗菌药物耐药性的风险。为缓解这种情况,人们对锌补充剂的潜力进行了探索,发现它是增强免疫系统的有效元素。锌还可通过增加纤毛摆动频率来阻止病毒进入。此外,利用纳米材料可以解决当前抗病毒药物存在的诸如作用范围窄和生物利用度低等局限性,纳米材料被认为是下一代重要的治疗选择。因此,新型抗病毒纳米制剂的开发将极大地有助于应对许多潜在挑战和知识空白。这篇综述文章深入探讨了COVID-19与抗菌药物耐药性(AMR)之间的相互关系以及抗击当前疫情的可能影响和现行策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee02/7963520/1194c7150c1f/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee02/7963520/791083c89461/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee02/7963520/aa1f190b0e5a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee02/7963520/683c779cbd3f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee02/7963520/1194c7150c1f/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee02/7963520/791083c89461/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee02/7963520/aa1f190b0e5a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee02/7963520/683c779cbd3f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee02/7963520/1194c7150c1f/gr3.jpg

相似文献

1
New threatening of SARS-CoV-2 coinfection and strategies to fight the current pandemic.新型冠状病毒2型合并感染的新威胁及应对当前大流行的策略。
Med Drug Discov. 2021 Jun;10:100089. doi: 10.1016/j.medidd.2021.100089. Epub 2021 Mar 17.
2
Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations (Archived)针对轻度至中度症状的高危冠状病毒(COVID-19)患者的单克隆抗体疗法(存档)
3
Current Strategies of Antiviral Drug Discovery for COVID-19.新型冠状病毒肺炎抗病毒药物研发的当前策略
Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021.
4
Antimicrobial Resistance as a Hidden Menace Lurking Behind the COVID-19 Outbreak: The Global Impacts of Too Much Hygiene on AMR.抗菌药物耐药性:新冠疫情背后潜藏的隐性威胁——过度卫生对耐药性的全球影响
Front Microbiol. 2020 Dec 15;11:590683. doi: 10.3389/fmicb.2020.590683. eCollection 2020.
5
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.SARS-CoV-2 及其他人类致病冠状病毒的抗病毒药物和可用药靶的现状。
Drug Resist Updat. 2020 Dec;53:100721. doi: 10.1016/j.drup.2020.100721. Epub 2020 Aug 26.
6
Evaluating And Referring Patients For Outpatient Monoclonal Antibody Therapy For Coronavirus In The Emergency Department (Archived)在急诊科评估并转诊患者接受冠状病毒门诊单克隆抗体治疗(存档)
7
Clostridioides difficile infection (CDI) during the COVID-19 pandemic.艰难梭菌感染(CDI)在 COVID-19 大流行期间。
Anaerobe. 2022 Apr;74:102518. doi: 10.1016/j.anaerobe.2022.102518. Epub 2022 Jan 19.
8
The interrelationships between antimicrobial resistance, COVID-19, past, and future pandemics.抗微生物药物耐药性、COVID-19 与过去和未来大流行之间的相互关系。
J Infect Public Health. 2021 Jan;14(1):53-60. doi: 10.1016/j.jiph.2020.10.018. Epub 2020 Dec 9.
9
Antiviral Potential of Nanoparticles-Can Nanoparticles Fight Against Coronaviruses?纳米颗粒的抗病毒潜力——纳米颗粒能对抗冠状病毒吗?
Nanomaterials (Basel). 2020 Aug 21;10(9):1645. doi: 10.3390/nano10091645.
10
Plant Spices as a Source of Antimicrobial Synergic Molecules to Treat Bacterial and Viral Co-Infections.植物香料作为治疗细菌和病毒混合感染的抗菌协同分子的来源。
Molecules. 2022 Nov 25;27(23):8210. doi: 10.3390/molecules27238210.

引用本文的文献

1
An insight into impact of nanomaterials toxicity on human health.纳米材料毒性对人类健康影响的深入洞察。
PeerJ. 2024 Sep 30;12:e17807. doi: 10.7717/peerj.17807. eCollection 2024.
2
Coinfections and Superinfections Associated with COVID-19 in Colombia: A Narrative Review.哥伦比亚 COVID-19 相关的合并感染和再感染:一项叙事性综述。
Medicina (Kaunas). 2023 Jul 20;59(7):1336. doi: 10.3390/medicina59071336.
3
Repurposing Polyether Ionophores as a New-Class of Anti-SARS-Cov-2 Agents as Adjunct Therapy.将聚醚离子载体重新用于作为辅助治疗的新型抗 SARS-CoV-2 药物。

本文引用的文献

1
A simplified viral RNA extraction method based on magnetic nanoparticles for fast and high-throughput detection of SARS-CoV-2.基于磁性纳米颗粒的简化病毒 RNA 提取方法,用于 SARS-CoV-2 的快速高通量检测。
Talanta. 2023 Jun 1;258:124479. doi: 10.1016/j.talanta.2023.124479. Epub 2023 Mar 23.
2
Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship.COVID-19 患者合并细菌感染和抗菌药物使用情况:抗生素管理视角下的回顾性队列研究。
Eur J Clin Microbiol Infect Dis. 2021 Apr;40(4):859-869. doi: 10.1007/s10096-020-04063-8. Epub 2020 Nov 2.
3
Curr Microbiol. 2023 Jul 6;80(8):273. doi: 10.1007/s00284-023-03366-1.
4
NLRP6 Induces Lung Injury and Inflammation Early in Brucella and Influenza Coinfection.NLRP6在布鲁氏菌和流感病毒合并感染早期诱发肺损伤和炎症。
J Pers Med. 2022 Dec 14;12(12):2063. doi: 10.3390/jpm12122063.
5
Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach.登革热疫情的防范:疫苗作为一种可行的方法
Vaccines (Basel). 2022 Nov 17;10(11):1940. doi: 10.3390/vaccines10111940.
6
Worldwide prevalence of microbial agents' coinfection among COVID-19 patients: A comprehensive updated systematic review and meta-analysis.全球 COVID-19 患者中微生物共感染的流行情况:一项全面更新的系统评价和荟萃分析。
J Clin Lab Anal. 2022 Jan;36(1):e24151. doi: 10.1002/jcla.24151. Epub 2021 Dec 1.
7
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.新冠疫情和疫苗更新:挑战与解决方案。
Front Cell Infect Microbiol. 2021 Sep 10;11:690621. doi: 10.3389/fcimb.2021.690621. eCollection 2021.
8
Bacterial coinfection among coronavirus disease 2019 patient groups: an updated systematic review and meta-analysis.2019冠状病毒病患者群体中的细菌合并感染:一项更新的系统评价与荟萃分析
New Microbes New Infect. 2021 Sep;43:100910. doi: 10.1016/j.nmni.2021.100910. Epub 2021 Jul 1.
9
COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern.新型冠状病毒肺炎与严重急性呼吸综合征冠状病毒2变体:当前挑战与健康关切
Front Genet. 2021 Jun 15;12:693916. doi: 10.3389/fgene.2021.693916. eCollection 2021.
Efflux Pump-Driven Antibiotic and Biocide Cross-Resistance in Isolated from Different Ecological Niches: A Case Study in the Development of Multidrug Resistance in Environmental Hotspots.
从不同生态位分离出的外排泵驱动的抗生素和杀菌剂交叉耐药性:环境热点地区多药耐药性发展的案例研究
Microorganisms. 2020 Oct 24;8(11):1647. doi: 10.3390/microorganisms8111647.
4
COVID-19 pandemic and antimicrobial resistance: Another call to strengthen laboratory diagnostic capacity in Africa.新冠疫情与抗菌药物耐药性:再次呼吁加强非洲的实验室诊断能力
Afr J Lab Med. 2020 Sep 23;9(1):1302. doi: 10.4102/ajlm.v9i1.1302. eCollection 2020.
5
Phytochemical delivery through nanocarriers: a review.植物化学物质通过纳米载体传递:综述。
Colloids Surf B Biointerfaces. 2021 Jan;197:111389. doi: 10.1016/j.colsurfb.2020.111389. Epub 2020 Oct 5.
6
The metabolic and immunological characteristics of pregnant women with COVID-19 and their neonates.COVID-19 孕妇及其新生儿的代谢和免疫特征。
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):565-574. doi: 10.1007/s10096-020-04033-0. Epub 2020 Oct 2.
7
Respiratory bacterial pathogen spectrum among COVID-19 infected and non-COVID-19 virus infected pneumonia patients.新型冠状病毒肺炎感染患者与非新型冠状病毒肺炎病毒感染的肺炎患者的呼吸道细菌病原体谱
Diagn Microbiol Infect Dis. 2020 Dec;98(4):115199. doi: 10.1016/j.diagmicrobio.2020.115199. Epub 2020 Sep 3.
8
Multivalent nanomedicines to treat COVID-19: A slow train coming.用于治疗新冠肺炎的多价纳米药物:姗姗来迟。
Nano Today. 2020 Dec;35:100962. doi: 10.1016/j.nantod.2020.100962. Epub 2020 Sep 4.
9
How can nanotechnology help to combat COVID-19? Opportunities and urgent need.纳米技术如何帮助对抗 COVID-19?机遇与迫切需求。
J Nanobiotechnology. 2020 Sep 5;18(1):125. doi: 10.1186/s12951-020-00685-4.
10
COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic.COVID-19:病理生理学、治疗选择、纳米技术方法以及抗击 SARS-CoV2 大流行的研究议程。
Life Sci. 2020 Nov 15;261:118336. doi: 10.1016/j.lfs.2020.118336. Epub 2020 Aug 23.